SCHEMBL16626796

SCHEMBL16626796

CN(Cc1cn(S(=O)(=O)c2cccc(F)c2)c2cc(Br)ncc12)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.39
DRD2 P14416 1/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HTR2A P28223 3/20 0.36
HTR2C P28335 3/20 0.36
SLC6A4 P31645 2/20 0.36
IDE P14735 1/20 0.35
RORC P51449 1/20 0.34
PTGDR Q13258 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
HTR7 P34969 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16618765 0.88 HTR6 (0.42) HTR6DRD2HDAC1HDAC2HDAC6
SCHEMBL16626488 0.87 HTR6 (0.42) HTR6HDAC1HDAC2HDAC6RORC
SCHEMBL16626658 0.85 HTR6 (0.39) HTR6DRD2HDAC1HDAC2HDAC6
SCHEMBL16626799 0.84 HTR6 (0.36) HTR6DRD2HDAC1HDAC2HDAC6
SCHEMBL16626798 0.82 TTK (0.39) HTR6HDAC1HDAC2HDAC6
SCHEMBL2416549 0.80 RIPK1 (0.39) HTR6HTR2CSLC6A4PTGDRPTGDR2
SCHEMBL16626661 0.78 RORC (0.45) HTR6HDAC1HDAC2HDAC6RORC
SCHEMBL19971353 0.78 HTR6 (0.41) HTR6DRD2HDAC1HDAC2HDAC6
SCHEMBL16618728 0.78 HTR6 (0.46) HTR6DRD2HTR2AIDE
SCHEMBL16626507 0.77 HDAC1 (0.38) HTR6HDAC1HDAC2HDAC6IDE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885DRD2 2007/4885HDAC1 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.